Bone marrow transplantation · 2020
Reduced-intensity conditioning is effective for hematopoietic stem cell transplantation in young pediatric patients with Diamond-Blackfan anemia.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Koyamaishi Shun, Kamio Takuya, Kobayashi Akie, Sato Tomohiko, Kudo Ko, Sasaki Shinya, Kanezaki Rika, Hasegawa Daiichiro, Muramatsu Hideki, Takahashi Yoshiyuki, Sasahara Yoji, Hiramatsu Hidefumi, Kakuda Harumi, Tanaka Miyuki, Ishimura Masataka, Nishi Masanori, Ishiguro Akira, Yabe Hiromasa, Sarashina Takeo, Yamamoto Masaki, Yuza Yuki, Hyakuna Nobuyuki, Yoshida Kenichi, Kanno Hitoshi, Ohga Shouichi, Ohara Akira, Kojima Seiji, Miyano Satoru, Ogawa Seishi, Toki Tsutomu, Terui Kiminori, Ito Etsuro
Аннотация
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of Diamond-Blackfan anemia (DBA). However, data regarding the optimal conditioning regimen for DBA patients are limited. We retrospectively compared the outcomes of DBA patients who underwent HSCT using either myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) regimens. The patients belonged to a cohort treated at our hospitals between 2000 and 2018. HSCT was performed in 27 of 165 patients (16.4%). The median age at the time of HSCT was 3.6 years. Stem cell sources included bone marrow for 25 patients (HLA-matched sibling donors, n = 5; HLA-mismatched related donors, n = 2; HLA-matched/mismatched unrelated donors, n = 18) or cord blood for 2 patients. MAC or RIC regimens were used in 12 and 15 patients, respectively. Engraftment was successful in all 27 patients who underwent HSCT. Three patients who underwent HSCT using MAC regimens developed sinusoidal obstruction syndrome. The 3-year overall survival (OS) and failure-free survival rates (FFS) post-transplantations were 95.2% and 88.4%, respectively, with no significant differences between MAC and RIC regimens. Our data suggest that HSCTs using RIC regimens are effective and obtain engraftment with excellent OS and FFS for young DBA patients.